Background. Uraemia is associated with endothelial dysfunction, but the effect of uraemic plasma on the gene expression pattern of human coronary arterial endothelial cells (HCAEC) has never been defined. Methods. HCAECs were exposed for 48 h to a culture medium supplemented with 20% uraemic vs normal plasma. We extracted mRNA and hybridized it onto Affymetrix HG-U133 Plus2 microarrays. We validated our findings for five genes of interest by real-time PCR and performed evaluations of cell proliferation and apoptosis in HCAECs exposed to uraemic vs normal plasma. Results. Six genes involved in the regulation of cell-cycle progression (CDK-1, topoisomerase II, PDZ-binding kinase, CDCA1, protein SDP35, E2F transcription factor 8) and two genes of the cholesterol efflux system (ABCA1 and ABCG1) were downregulated in HCAECs exposed to uraemic plasma (>1.75-fold change vs normal). Real-time PCR confirmed the down-regulation observed in the microarray experiment. Cell proliferation was significantly decreased in HCAECs exposed to uraemic vs normal plasma for 48 h (86 vs 95% of serum-starved control, P ¼ 0.006). Exposure to uraemic plasma for 48 h was associated with increased apoptosis of HCAEC as compared with normal plasma (7.7 vs 2.8%, P < 0.001), a phenomenon that was further enhanced when oxidized LDLs (150 mg protein/ml) were added to the medium containing uraemic plasma (16.9 vs 7.7%, P < 0.001). Conclusions. The down-regulation of genes involved in cell-cycle progression and cholesterol efflux from HCAECs exposed to uraemic conditions could contribute to enhancing endothelial dysfunction and atherosclerosis in patients with chronic renal failure.
Introduction
In the past decade, the important role of endothelial cell (EC) dysfunction in the pathogenesis of atherosclerosis (ASO) has been clearly demonstrated [1] [2] [3] [4] [5] [6] [7] . Proatherogenic factors such as oxidized lipids, diabetes mellitus and tobacco smoking are associated with EC dysfunction [8] [9] [10] [11] and apoptosis [12] [13] [14] . Both EC dysfunction and apoptosis induce multiple biological effects that can mediate the progression and clinical expression of ASO. They compromise vasoregulation [1] [2] [3] [4] [5] [6] [7] , enhance blood coagulation [15, 16] , promote infiltration of inflammatory cells and lipids into the intima [17, 18] , and increase vascular smooth muscle cell (VSMC) migration and proliferation [19, 20] .
The mortality rate from cardiovascular disease (CVD) in patients who suffer from chronic renal failure (CRF) is at least 3.5 times that of the general population [21] . While the high prevalence of traditional risk factors for ASO undoubtedly contributes to the accelerated rate of CVD in patients with CRF [22, 23] , they account for only a fraction of the excessive burden of heart disease experienced by these patients [24] . Hence, other mechanisms have been suggested to explain the accelerated ASO sustained by patients with kidney disease. CRF is associated with endothelial dysfunction [25] [26] [27] [28] . The impairment in endotheliumdependent vasodilatation observed in these patients is correlated with the severity of renal failure [25] . In addition, EC dysfunction has been reported to represent an independent risk factor for mortality in patients undergoing haemodialysis [29] .
The mechanisms involved in CRF-associated endothelial dysfunction remain obscure. Some evidence suggests that accumulating uraemic solutes can induce endothelial dysfunction. For instance, hyperhomocysteinaemia is associated with impaired endothelium-dependent vasodilation in both normotensive and hypertensive subjects [30] . Advanced glycation end products can increase endothelial permeability [31] and the expression of endothelial adhesion molecule [32] . However, the gene expression pattern of ECs induced by uraemic plasma and solutes is unknown at the present time.
The aim of this study was to determine which genes were differentially expressed in human coronary arterial endothelial cells (HCAECs) exposed to a medium supplemented with uraemic vs normal human plasma, using DNA microarrays. We then validated the microarray findings with real-time PCR techniques and assessed their significance by performing functional assays.
Subjects and methods

Overview
HCAECs were grown in endothelial culture medium and exposed to a medium supplemented with 20% uraemic or 20% normal plasma for 48 h. RNA was extracted, reverse transcribed into cDNA and hybridized onto Affymetrix Õ GeneChips for microarray analysis. Results of the microarray analysis were validated with real-time PCR techniques. In addition, functional assays (i.e. evaluation of cell proliferation and evaluation of apoptosis) were performed to assess the significance of microarray findings. The ethics review board of the Centre Hospitalier de l'Universited e Montre´al and Hoˆpital du Sacre´-Coeur de Montre´al gave their approval to the study.
Management, collection and provenance of human plasma
Blood samples were collected from healthy volunteers and end-stage renal disease (ESRD) patients on thrice-weekly chronic haemodialysis. All participants provided informed consent. Blood was collected in 10 ml tubes containing ethylenediaminetetraacetic acid (EDTA), sent on ice to the laboratory, and centrifuged (1300g for 10 min). Plasma was then aliquoted and stored at À808C. Plasma was not pooled. Each plasma was used for an individual experiment. Two different subsets of ESRD patients provided plasma for the different experiments conducted during this study: microarray analysis (n ¼ 6), cell proliferation assay and apoptosis assay (n ¼ 10). The characteristics of patients providing plasma in the two uraemic groups are provided in Table 1 . Similarly, different healthy volunteers provided plasma for the various experiments. Three healthy volunteers served as a control group for the microarray study. Their mean age was 40.0 AE 5.0 years, and 66% were of female gender. For the cell proliferation and the apoptosis assays, 10 healthy volunteers served as controls. They were matched for gender and age (5 year calliper) with each uraemic subject. All control subjects had normal kidney function, no history of vascular disease, diabetes, dyslipidaemia or smoking. They used no medication.
Culture of endothelial cells
HCAECs were obtained from Clonetics (San Diego, CA) and used at passages 2 up to 4. The cells were seeded on gelatin-coated (1%) tissue culture plates (Becton-Dickinson, Franklin Lakes, NJ) and cultured in endothelial culture medium (EBM-EGM-MV; Clonetics, San Diego, CA). They were maintained in a humidified atmosphere containing 5% CO2-95% air at 378C. Monolayers of confluent HCAECs were then exposed to EBM (Clonetics, San Diego, CA) supplemented with either 20% plasma from healthy volunteers (normal group) or 20% plasma from patients with ESRD (uraemic group) for 48 h. We studied HCAECs at confluence to reproduce in vivo conditions, in which the endothelium does not have a high cell turnover and its cells are not in the exponential growth phase [33] . We chose to expose the cells for 48 h since our aim was to mimic chronic exposure to the uraemic environment, although this time point did not permit us to observe early events.
RNA extraction and microarray hybridization
After exposure to the different experimental conditions, HCAECs were collected with the use of trypsin followed by centrifugation. They were washed in phosphate-buffered saline (PBS), centrifuged, and frozen at À808C. RNA extraction was performed using a commercially available kit (RNeasy, QIAgen, Burlington, ON, Canada). The quality of the RNA was monitored by gel electrophoresis and a 2100 Bioanalyzer, using the RNA 6000 Nano LabChip kit (Agilent Technologies, Germany). RNA was transcribed into cDNA with a double reverse transcriptase-PCR technique, 
and in vitro transcription was performed to generate biotin-labelled cRNA for subsequent hybridization on HG-U133 Plus2 GeneChips Õ (Affymetrix, Santa Clara, CA). This chip contains 38,500 well-characterized human genes, and further information on its characteristics can be found at http://www.affymetrix.com/support/technical/ datasheets/human_datasheet.pdf. The detailed protocols used for transcription and hybridization are available at https://genomequebec.mcgill.ca/nanuqAdministration/nanuqadministration/protocols.go. There were six biological replicates in the uraemic group, and three in the normal group. We did not perform technical replicates. Hybridized target cRNA was stained with streptavidin phycoerythrin and arrays were scanned using a GeneArray Õ Scanner (Affymetrix, Santa Clara, CA) at an excitation wavelength of 488 nm.
Real-time PCR validation
RNA extracted from HCAECs in the previous experiment was reverse transcribed in cDNA by reverse transcriptase-PCR using Super-Script preamplification system (Invitrogen, ON, Canada). The PCR reaction (958C for 15 min, 40 cycles of 958C for 15 s, 608C for 30 s, 728C for 30 s) was performed using conventional PCR conditions, with a Rotor-gene 3000 Real-Time Centrifugal DNA Amplification System (Corbett Tumor Tissues Research, NSW, Australia). We used the Quantitect TM SYBR Green PCR (Qiagen, ON, Canada) reaction mixture according to the manufacturer's instructions. We performed serial dilutions to generate a standard curve for each gene tested in order to define the efficiency of the Q-PCR reaction, and a melt curve analysis was done to confirm the specificity of the reaction. Based on the stability of its expression in microarray experiments, we used primers for the GAPDH gene as internal controls. The parameter CT (cycle threshold) value was measured to determine starting copy number of target genes using the standard curve. The sequences for ABCA1 primers were as follows: 
Evaluation of cell proliferation
HCAECs were cultured to 80% confluence and exposed for 48 h to EGM containing either 20% plasma from patients on haemodialysis (n ¼ 10) or 20% plasma from healthy volunteers (n ¼ 10). Measurement of BrdU incorporation during DNA synthesis was performed using a Cell Proliferation ELISA BrdU (colorimetric) kit (Roche Diagnostics, GmbH, Germany) according to the protocol provided by the manufacturer and as we described previously [19, 34, 35] .
Evaluation of apoptosis
HCAECs were cultured to confluence and exposed for 48 h to the following four different experimental conditions: HCAECs were exposed to EGM containing 20% plasma from healthy volunteers (n ¼ 10), 20% normal plasma supplemented with oxLDLs (150 mg protein/ml; Biomedical Technologies Inc., MA, USA) (n ¼ 10), 20% plasma from uraemic patients on haemodialysis (n ¼ 10), and 20% uraemic plasma supplemented with oxLDLs (150 mg protein/ml) (n ¼ 10). We assessed apoptosis with fluorescence microscopy after staining HCAECs with Hoechst 33342 [2 0 -(4 ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2.5 0 -bi-1H-benzimidazole;HT)] and propidium iodide (PtdIns), and used a positive control for apoptosis (serum-starved conditions, data not shown) as described in previous work [17, [34] [35] [36] .
Statistical analysis
In the microarray analysis, summary measures for the expression signal of each probeset was provided (in log base 2) after background correction and quantile normalization, with the robust multi-chip averaging method (RMA) [37] . The average expression of each probeset within each treatment group was calculated. The differences (log (u) À log (n)) between the averages in the uraemic (u) and the normal (n) group were found for each probeset, and are equivalent to the logged fold change log (u/n). We then performed an inverse log function and considered that genes were differentially expressed when the unlogged absolute value of the ratio of the average signal in the uraemic group over the average signal in the normal group was greater than 1.75. We identified the genes of interest with the Affymetrix Õ website, which links probesets from the microarray to their respective gene annotation [38] . In the real-time PCR analysis, the expression of each gene of interest was reported as a ratio of its expression over that of GAPDH. We averaged these ratios in the uraemic and the normal group. We tested the difference in the mean expression of each gene of interest in the uraemic vs the normal group with a two-tailed, two-sample equal variance Student's t-test. We measured cell proliferation as BrdU incorporation in each group, compared with serum-starved conditions. Since the Shapiro-Wilk W statistic failed to reject the null hypothesis of a normal distribution for BrdU incorporation and percentage of apoptotic cells, we used a two-tailed two-sample equal variance Student's t-test to verify whether mean BrdU incorporation and mean percentage of apoptotic cells differed between uraemic and normal conditions.
Results
Microarray experiment
In brief, HCAECs were grown in EBM-EGM-MV and used at confluence. They were exposed to a medium supplemented with 20% uraemic or 20% normal plasma for 48 h. RNA was extracted, transcribed in cDNA and hybridized onto Affymetrix Õ HG-U133 Plus2 GeneChips. Using the aforementioned predetermined criteria, we found 11 genes to be Uraemic and gene expression in endothelial cells 411 differentially expressed between the two experimental conditions ( Table 2 ). Six genes (CDK-1, topoisomerase II, PDZ-binding kinase, CDCA1, protein SDP35, E2F transcription factor 8) are involved in cell-cycle progression. All were down-regulated in uraemic vs normal conditions. Two genes (ABCA1 and ABCG1) coded for proteins involved in cholesterol efflux from the cells. Both were also down-regulated in uraemic conditions. CXCL-11, a chemokine, was down-regulated in uraemic conditions, whereas two members of the cytochrome P450 family (CYP 26B1, CYP 1A1) were up-regulated in the uraemic group.
Real-time PCR validation
We performed real-time PCR validation for five genes of interest on the same RNA that was extracted from HCAECs in the microarray experiment. We chose to validate both genes involved in cholesterol efflux from the cells, and three genes (CDK-1, topoisomerase II and CDCA1) involved in cell-cycle progression (Table 3) . We validated CDCA1 for the magnitude of its fold change in the normal vs uraemic group. CDK-1 was chosen for its crucial role in mitosis initiation and topoisomerase-2 for the evidence supporting its use as a cell proliferation marker in various tumour types [39, 40] . By real-time PCR, both genes involved in cholesterol efflux from the cells were down-regulated in uraemic conditions. Hence, we observed lower ABCA1/GAPDH (0.61 vs 1.48, P ¼ 0.03) and ABCG1/GAPDH ratios (0.71 vs 1.06, P 0.01) in uraemic vs normal conditions. For genes involved in cell-cycle progression, the CDCA1/ GAPDH (0.56 vs 1.01, P 0.01), CDK-1/GAPDH (0.63 vs 1.26, P 0.01) and topoisomerase II/GAPDH (0.39 vs 0.88, P 0.01) ratios were all significantly lower in HCAEC exposed to uraemic vs normal conditions.
Cell proliferation
Given the observed down regulation of many genes involved in cell-cycle progression, we sought to evaluate the impact of the uraemic environment on EC proliferation. HCAECs were exposed for 48 h to a culture medium supplemented with 20% uraemic vs normal plasma. BrdU incorporation was significantly decreased in HCAEC exposed to uraemic vs normal plasma (86.0 vs 95.4% of serum starved milieu, P ¼ 0.006). Hence, in a uraemic environment, EC proliferation was decreased by 10% with respect to that observed in normal conditions, supporting the microarray findings (Figure 1 ).
Apoptosis
Given the observed down regulation of genes involved in cholesterol efflux from cells (ABCA1 and ABCG1), we sought to evaluate the impact of uraemic plasma on cholesterol-induced apoptosis of ECs. HCAECs were grown in EBM-EGM-MV and used at confluence. They were then exposed for 48 h to EBM containing 20% plasma from healthy volunteers alone or supplemented with oxidized low-density lipoproteins (oxLDLs), and to EBM containing 20% plasma from uraemic subjects alone or supplemented with oxLDLs. There was a significant increase in the percentage of apoptotic cells (Figure 2 ) at 48 h when HCAECs were exposed to uraemic plasma alone vs normal plasma (7.7 vs 2.8%, P 0.001). A further significant increase was observed when oxLDLs and uraemic plasma were combined compared with medium containing uraemic plasma alone (16.9 vs 7.7%, P 0.001). The oxLDLs alone had a pro-apoptotic effect when compared with normal plasma alone (13.1% vs 2.8%, P 0.001).
The percentage of necrotic cells was 1.9% in the presence of medium supplemented with normal plasma, and 1.2% with uraemic plasma.
Discussion
Uraemic patients experience an increased burden of CVD [21] . Endothelial dysfunction, a major player in the pathogenesis of ASO, is also associated with CRF [25] [26] [27] [28] . However, the mechanisms that underline this association remain unclear. The gene expression profile of ECs in response to uraemia had never been examined previously. In this study, we found that exposure to uraemic plasma causes a down-regulation of genes involved in cholesterol efflux from the cells and increases apoptosis in HCAECs. Furthermore, HCAECs respond to uraemic plasma with a downregulation of genes involved in cell-cycle progression and decreased cell proliferation. Two genes (ABCA1 and ABCG1) coding for proteins involved in cholesterol efflux from cells were found to be down-regulated in uraemic conditions. ABCG1 plays a critical role in lipid homeostasis by controlling efflux of cellular cholesterol to HDL [41] . Disruption of ABCG1 in mice results in massive accumulation of lipids in macrophages within multiple tissues when a high-fat diet is administered [41] . Although the role of ABCG1 in cholesterol efflux from macrophages is well recognized, its participation to lipid removal from ECs is not established [42, 43] . Whether uraemia modulates ABCG1 expression in macrophages or other cell types is presently unknown.
ABCA1 is a membrane-associated protein that plays a crucial role in the cellular apolipoprotein-mediated lipid removal pathway [44] . In humans, homozygous mutations cause Tangier's disease [44] , a condition associated with extremely low high-density lipoprotein (HDL) levels, high triglycerides (TG) and a 6-fold increase in the prevalence of cardiovascular disease. In a large cohort of patients [45] and in two smaller observational studies [46, 47] , heterozygosity for ABCA1 mutations was associated with an increase in risk of ischemic heart disease, low HDLs and high TG. Interestingly, patients suffering from CRF often exhibit a similar pro-atherogenic phenotype.
Many risk factors for ASO such as increased glucose levels [13] , age [14] and oxLDLs [12] have pro-apoptotic effects on ECs. Apoptosis of ECs, in turn, is associated with endothelial dysfunction [48] and is believed to play a role in the development of ASO [49, 50] . We speculated that uraemic plasma, by down-regulating cholesterol efflux mechanisms in HCAEC, would make these cells more susceptible to apoptosis, especially in the presence of oxLDLs. We observed an increase in apoptotic cell death when HCAECs were exposed to uraemic plasma. Apoptosis was further enhanced when we added oxLDLs to uraemic plasma. Although this is a novel finding, it is consistent with other recent indirect evidence. For instance, urea-carbamylated LDLs, which are high in patients with CRF, can induce apoptosis in HCAECs [51] . Whether the higher levels of apoptosis we observed result from intracellular lipid accumulation due to ABCA1 and ABCG1 down-regulation remains speculative and further studies will be needed to address this issue. However, our results provide evidence that a uraemic environment promotes EC apoptosis, which can lead to the development of ASO and its clinical manifestations. Furthermore, the elevated levels of oxLDLs that are frequently Percent apoptotic HCAECs when exposed to medium supplemented with normal or uraemic plasma and oxLDLs. Difference in mean percent apoptotic cells in HCAEC exposed to medium supplemented with uraemic (n ¼ 10) vs normal (n ¼ 10) plasma (7.7 vs 2.8%, P < 0.001), with oxLDLs and uraemic (n ¼ 10) plasma vs uraemic (n ¼ 10) plasma alone (16.9 vs 7.7%, P < 0.001), or with oxLDLs and normal (n ¼ 10) plasma vs normal (n ¼ 10) plasma alone (13.1 vs 2.8%, P < 0.001).
Uraemic and gene expression in endothelial cells 413 encountered in patients with CRF [52] can enhance EC apoptosis and CVD development. In conditions promoting endothelial injury and apoptosis, the endothelial layer should have an intact repair capacity to maintain integrity and function. A decrease in this capacity may lead to ASO and its clinical manifestations. Although the repair capacity of resident ECs is hard to quantify in vivo, our results suggest that uraemia diminishes it. We observed a down-regulation of several genes involved in cellcycle progression in uraemic conditions. CDK-1 is a cyclin-dependent kinase that forms a complex with cyclin B. This complex, M-Cdk, plays a crucial role in the early stages of mitosis by phosphorylating multiple regulatory and structural proteins [53] . The M-Cdk complex induces the assembly of the mitotic spindle and ensures proper chromosomal attachment to the spindle. Furthermore, it is involved in chromosome condensation, nuclear membrane disruption, and actin cytoskeleton rearrangement. Topoisomerase II is a nuclear enzyme involved in chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication [53] . The expression of topoisomerase II is cell-cycle dependent with both protein levels and catalytic activity peaking at G2/M [54] . It serves as a cell proliferation marker in various tumor types [39, 40] . Finally, CDCA1 is a protein involved in the attachment of kinetochores to microtubules. Its experimental depletion in HeLa cells has been shown to induce a cell-cycle block and the death of mitotic cells [55] .
In agreement with the gene pattern we defined, we observed decreased cell proliferation when HCAECs were exposed to uraemic conditions. Also consistent with our findings, the uraemic solutes P-cresol and indoxyl sulfate have been reported to decrease endothelial wound repair in HUVECs, while P-cresol decreases cell proliferation [56] . Furthermore, asymmetrical dimethylarginine (ADMA) accelerates endothelial senescence [57] and uraemic levels of oxalic acid decreased EC proliferation and migration in HUVECs [58, 59] . ADMA is elevated in patients with renal failure, and constitutes an independent risk factor for cardiovascular events in these patients, as well as in the general population [60] .
The present study has some limitations. In the microarray experiments, all our uraemic subjects had prior vascular disease and were older than controls. Therefore, we could not study distinct gene expression profiles in the plasma of those with and without CVD. Hence, we cannot rule out the possibility that gene expression changes in HCAECs are induced from solutes being present in the plasma as a result of vascular disease, age or medication rather than as a result of uraemia per se. However, we did perform validating functional assays (cell proliferation and apoptosis assays) on uraemic subjects who were matched for gender and age with their respective controls, which makes it unlikely for these two factors to explain our results. Although the real-time PCR validation studies were performed on the same RNA material as the microarray experiments, we did not have access to sufficient patient plasma from the original sample to perform the cell proliferation and apoptosis assays. We used new experimental subjects for the latter part. However, the fact that the functional assays support our previous findings even when plasma from different patients are used adds robustness to our results.
In conclusion, we found that exposure to uraemic plasma is associated with a down-regulation of genes involved in cholesterol transport and may create conditions that promote EC apoptosis and injury, a phenomenon that is accentuated by the presence of oxLDLs. Exposure to uraemic plasma is also associated with a down-regulation of genes involved in cell-cycle progression and decreased EC proliferation. Our results suggest that the combined effect of uraemia on apoptosis and proliferation of HCAECs can make the endothelial layer dysfunctional and proatherogenic in patients with CRF. Taken together, these observations provide novel insights into the pathogenesis of ASO associated with uraemia.
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